Investors
News Releases
- April 30, 2020Annovis Bio Announces Plans for a New Phase II Clinical Trial to Treat 68 Parkinson’s and Alzheimer’s Patients
- April 23, 2020Annovis Bio Publishes Results of Alzheimer’s and Parkinson’s Animal Studies
- April 13, 2020Annovis Bio to Hold Investor Webinar and Q&A Session with CEO on April 14
- February 27, 2020Annovis Awarded $1.7 Million NIH Grant for ANVS401 Chronic Toxicology Studies
- February 20, 2020Annovis Issued Patent for Method of Treating Parkinson’s Disease and Other Lewy Body Diseases
- February 13, 2020Annovis Bio Announces Update on Phase II Clinical Trial for Alzheimer’s Disease
- January 31, 2020Annovis Bio Announces Closing of Initial Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares
- January 29, 2020Annovis Bio Announces Pricing of Initial Public Offering
Events & Presentations
-
Annovis Bio - Phase III PD Data
-
AD & PD Data Updates - July 2024
Filings
Filings
Description
Date Filed
Available Formats
E-mail Alerts
Back to Top